Affinity Asset Advisors, LLC Arcellx, Inc. Transaction History
Affinity Asset Advisors, LLC
- $560 Million
- Q4 2024
A detailed history of Affinity Asset Advisors, LLC transactions in Arcellx, Inc. stock. As of the latest transaction made, Affinity Asset Advisors, LLC holds 425,000 shares of ACLX stock, worth $27.5 Million. This represents 5.78% of its overall portfolio holdings.
Number of Shares
425,000
Previous 400,000
6.25%
Holding current value
$27.5 Million
Previous $33.4 Million
3.1%
% of portfolio
5.78%
Previous 5.77%
Shares
11 transactions
Others Institutions Holding ACLX
# of Institutions
224Shares Held
45.1MCall Options Held
434KPut Options Held
433K-
Paradigm Biocapital Advisors LP New York, NY4.37MShares$283 Million12.7% of portfolio
-
Nea Management Company, LLC Timonium, MD3.75MShares$243 Million20.37% of portfolio
-
Black Rock Inc. New York, NY3.52MShares$228 Million0.0% of portfolio
-
Perceptive Advisors LLC New York, NY3.48MShares$225 Million8.84% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.33MShares$216 Million0.0% of portfolio
About Arcellx, Inc.
- Ticker ACLX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,819,200
- Market Cap $2.84B
- Description
- Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It...